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Abstract
Objective: Metabolic syndrome and chronic kidney disease are major public health challenges. This 
study aimed at determining the prevalence of metabolic syndrome among chronic kidney disease patients.
Methods: One hundred and sixty patients were enrolled. Glomerular filtration rates were estimated using 
the Cockcroft Gault formula. Metabolic syndrome was defined by the presence of ≥ 3 of the following: 
Central obesity (waist circumference of >102 cm in males or >88 cm in females); Hypertriglyceridemia 
>150 mg/dL, low HDL cholesterol (<40 mg/Dl in males and <50 mg/dL in females), Hypertension 
(>130/85mmHg), Fasting plasma glucose >100 mg/dL.
Results: The overall prevalence of metabolic syndrome was 67.5%, CKD stage 5 had the highest 
prevalence (85.1%) (p = 0.165). Prevalence among diabetics was 82% (p <0.000). CKD stage and number 
of metabolic syndrome criteria positively correlated.
Conclusion: approximately seven out of every 10 CKD patients had metabolic syndrome. It was more 
associated with advanced CKD. Diabetics compared to non-diabetics were 1.5 times more predisposed.
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Prévalence du syndrome métabolique chez les patients atteints 
d'insuffisance rénale chronique fréquentant un hôpital tertiaire au 
Nigeria - Une étude transversale.
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Abstrait
Objectif: Le syndrome métabolique et les maladies rénales chroniques constituent des défis majeurs en 
matière de santé publique. Cette étude visait à déterminer la prévalence du syndrome métabolique chez les 
patients atteints d'insuffisance rénale chronique.
Méthodes: Cent soixante patients ont été recrutés. Les taux de filtration glomérulaire ont été estimés à 
l'aide de la formule de Cockcroft Gault. Le syndrome métabolique était défini par la présence de ≥ 3 des 
cas suivants: obésité centrale (tour de taille> 102 cm chez les mâles ou> 88 cm chez les femelles); 
Hypertriglycéridémie> 150 mg / dL, cholestérol HDL faible (<40 mg / Dl chez les hommes et <50 mg / dL 
chez les femmes), hypertension (> 130/85 mmHg), glycémie plasmatique à jeun> 100 mg / dL.
Résultats: La prévalence globale du syndrome métabolique était de 67,5%, le stade 5 de la maladie rénale 
chronique était le plus élevé (85,1%) (p = 0,165). La prévalence chez les diabétiques était de 82% (p 
<0,000). Stade CKD et nombre de critères du syndrome métabolique corrélés positivement.
Conclusion: environ 7 patients atteints de néphropathie chronique sur 10 avaient un syndrome 
métabolique. Il était plus associé à la maladie rénale chronique. Les diabétiques comparés aux non-
diabétiques étaient 1,5 fois plus prédisposés.
Mots-clés: syndrome métabolique, maladie rénale chronique, diabète sucré
*Corresponding Author 
Olokor A.B.
1Nephrology unit, Department of Internal Medicine, University of Benin. Benin City. Nigeria
2Obstetrics and Gynaecology Department, University of Benin. Benin City. Nigeria
Received: June 24, 2018 Accepted: August 4, 2018   Published: September 30, 2018
http://orcid.org/0000-0002-162-8569
Email: Sweetafe@yahoo.com
Res. J. of Health Sci. Vol 6(3), July/Sept., 2018                                                       108
Research Journal of Health Sciences subscribed to terms and conditions of Open Access publication. Articles are distributed under the terms of 
Creative Commons Licence (CC BY-NC-ND 4.0). (http://creativecommons.org/licences/by-nc-nd/4.0).
http://dx.doi.org/10.4314/rejhs.v6i3.2
Prevalence of MetS among CKD patients                                                     Olokor and Olokor
INTRODUCTION
The metabolic syndrome (MetS) and 
chronic kidney disease (CKD) are two major 
public health challenges. Metabolic 
syndrome is a cluster of biochemical and 
physical abnormalities which include central 
obesity, hypertriglyceridemia, low HDL 
cholesterol, hypertension, and Type 2 
diabetes .The presence of the metabolic 
syndrome confers a risk for cardiovascular 
disease on an individual as its individual 
components are risk factors in themselves for 
cardiovascular events. The National 
Cholesterol Education Program/Adult 
Treatment Panel (NCEP ATP) III 2001 
criteria defines the metabolic syndrome as 
the presence of >3 of the following: Central 
obesity (waist circumference of >102 cm in 
m a l e s  o r  > 8 8  c m  i n  f e m a l e s ) ;  
Hypertriglyceridemia >150 mg/dL, low HDL 
cholesterol (<40 mg/Dl in males and <50 
mg/dL in  females) ,  Hyper tens ion  
(>130/85mmHg), Fasting plasma glucose 
>100 mg/dL or previously diagnosed Type 
2diabetes or being on specific medications 
for these conditions (1).
CKD on the other hand, is defined as 
a glomerular filtration rate (GFR) less than 
260mL/min/1.73m  and/or kidney damage 
determined by abnormal findings in urine, 
such as proteinuria, albuminuria, haematuria, 
abnormal imaging, and/or histology, lasting 
for 3 months or more (2). It has also been 
noted to be a cardiovascular risk factor. 
Mortality in CKD patients is reported to be 
higher than in the general population (3).
The relationship between CKD and 
MetS may be two way as MetS may 
contribute to the progress of CKD and 
therefore make the risk of CVD in CKD at 
any stage, higher (4,5). MetS in return 
consists of components which are risk factors 
for CKD. All component of MetS has been 
associated with both CKD incidence and 
progression.A study in Okinawa Japan (6) 
showed that the relationship between the 
number of metabolic syndrome components 
and the prevalence of CKD is linear, the same 
linear relationship was noticed amongst the 
Chinese (7), hence the presence of MetS in 
CKD confers a worse prognosis and would 
indeed increase the mortality rate from 
cardiovascular events (8).
Studies have shown the prevalence 
rate of MetS in CKD to range from 37.5 –65 
% (9-11). A study carried out in the US over a 
5 year period amongst 3,939 CKD patients 
revealed a MetS prevalence of 65%, with a 
prevalence as high as 87.5% in the diabetics 
and 44.3% in the non-diabetics (11). This was 
higher than the prevalence of MetS in the 
general population in another US study in 
which the prevalence of MetS in the general 
population ranged between 22 – 35 % (10).
Given the previously reported 
relationship between MetS and CKD, this 
study aimed at determining the prevalence of 
MetS in CKD at our facility.
MATERIALS AND METHODS
This was a hospital-based cross-
sectional analytical study conducted at the 
University of Benin Teaching Hospital 
(UBTH). Patients with CKD were 
consecutively recruited upon presentation to 
either the Nephrology clinic, Dialysis, or 
Accident and Emergency units of the 
hospital. Informed consent was obtained 
from all participants. Ethical approval was 
obtained from the Ethics Committee of 
University of Benin Teaching Hospital.
Patients were stratified based on the 
stage of CKD using the NKF/KDOQI staging 
(4).One hundred and sixty newly diagnosed 
or previously known CKD patients on  
conservative management or renal 
replacement therapy (RRT) were recruited. 
The primary outcome of this study was the 
estimation of the prevalence of the metabolic 
syndrome among CKD patients.
 A r e s e a r c h e r - a d m i n i s t e r e d  
questionnaire was used to collect data. The 
waist circumference in centimetres before 
breakfast was measured in the horizontal 
plane at the level of the natural waist-line 
(taken to be at the umbilicus). A non-
stretchable tape was used. All subjects were 
instructed to observe an overnight fast for 10-
12 hours before blood sample collection. 
Each subject had their age noted, weight 
taken and serum creatinine measured from 
which GFR was estimated using the 
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Cockcroft-Gault formula. Fasting blood 
glucose (FBG), and fasting serum lipids were 
also measured.
Data obtained were entered into 
SPSS version 17 and analysed. Continuous 
variables were presented as means and 
standard deviation (SD) while discrete 
variables were presented as percentages. 
Student's t test, cross-tabulation, and Chi 
square test were used as appropriate. The 
confidence interval was set at 95% limit, with 
the level of significance being p values< 
0.05.
RESULTS
 The participants consisted of 101 
males (63.1%) and 59 females (36.9%) with 
age ranging from 18 -80 years. The mean age 
was 45.9 ± 16.0 years for men and 42.09 ± 
14.9 years for women; participants older than 
60 years accounted for 22.5%. Thirty- nine 
(24.4%) participants had diabetes mellitus, 
116 (72.5%) had hypertension, 106 (66.2%) 
hadhypertriglyceridemia and low HDL 
cholesterol was seen in 117(73.1%) patients. 
Fifty-five (34.3%) patients had central 
obesity. This is as shown in table 1
MetS was found in 108 (67.5%) 
participants with a greater percentage of the 
female 42 (71.2%) having the syndrome.
Metabolic syndrome was noted in 
82% of the diabetic patients, and in 53% of 
the non-diabetics. This was statistically 
significant (p <0.001). 
The association between stage of 
CKD and the number of metabolic syndrome 
components present, using the Spearman's 
rank order correlation is shown in table 2. 
There was a weak positive correlation 
between CKD stage and number of metabolic 
syndrome components present. This was 
however not statistically significant (rho = 
0.147, p= 0.064 ).
There was a linear trend in MetS 
prevalence with increasing CKD stage as 
shown in table 3.
DISCUSSION
Metabolic syndrome in CKD was 
common in this study accounting for 67.5 %. 
Approximately seven out of every ten CKD 
patient that was seen in hospital had MetS. 
Our finding was comparable to recent data 
from the Chronic Renal Insufficiency Cohort 
(CRIC) study carried out in the US in which 
the prevalence was 65% (11). A similar by 
Ogbu et al in Calabar in which 168 
participants were studied however, reported a 
lower prevalence of 41%. Previous studies 
also found that each component of MetS was 
independently associated with both CKD 
incidence and progression (4). Like our 
findings, Ogbu et al reported an elevated 
systolic blood pressure as the commonest 
component of MetS (prevalence of 72.5% Vs 
72.6% respectively) with the least prevalent 
component being hyperglycemia. This was in 
variance with the CRIC study in which the 
most and least prevalent components were 
hypertension and raised triglyceride levels 
respectively (11). Variations in the 
prevalence of diabetes mellitus in the 
different populations may explain the 
different prevalence reported.
Elevated BP is an aetiological as well 
as a progressive factor for CKD. 
Hypertension has been shown to be the 
strongest risk factor for individuals with 
MetS to develop CKD (12).
The number of MetS components 
seen in an individual was shown to increase 
the risk of developing CKD (13). Our study 
showed a positive correlation between 
number of MetS components present and the 
stage of CKD. In all stages, majority of the 
participants had at least 3 components of 
MetS. All the CKD patients had at least one 
component of MetS. A linear association has 
been noted between the number of MetS 
components and the prevalence of CKD in 
previous studies (14).
Our study revealed that the 
prevalence of MetS increased as CKD 
progressed and was noted in 85% of patients 
in stage 5 CKD. This was much higher than 
the prevalence of MetS obtained from other 
studies of patients on hemodialysis (41.7% - 
50%) (1, 4).
Diabetic patients had a higher 
prevalence of MetS when compared with the 
non-diabetics. This could be explained by the 
fact that MetS is also associated with incident 
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overt type 2 diabetes and given the fact that 
insulin resistance is common to MetS and 
type 2 DM (15,16).
CONCLUSION
In conclusion, our study showed that 
approximately seven out of every ten CKD 
patients had metabolic syndrome and it was 
more associated with advanced CKD. 
Diabetics compared to non-diabetics were 
1.5 times more predisposed. Screening for 
MetS in CKD may reduce associated 
cardiovascular mortality.
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Table 1: Sociodemographic characteristics and metabolic  
syndrome components among study participants.  
 
CHARACTERISTICS MEAN ± SD  
AGE     Male 
             Female 
45.9 ± 16.0 
42.09 ±14.9 




101   (63.1%) 
59     (36.9%) 










55 (34.3%)  
117 (73.1%) 
Reduced HDL-C 





Table 2: Association between stage of CKD and the number of metabolic  
syndrome components present  
 





1 2 3 4 5 
 1 0(0.0) 2(66.7) 1(33.3) 0(0.0) 0(0.0) 
2 1(33.3) 1(33.3) 1(33.3) 0(0.0) 0(0.0) 
3 5(9.6) 13(25.0) 20(38.5) 11(21.2) 3(5.8) 
4 3(3.7) 24(29.6) 35(43.2) 18(22.2) 1(1.2) 






Table 3: The prevalence of MetS by CKD stage amongst study participants 
 
CKD STAGE  
PRESENCE OF MetS 
FREQUENCY(%) 
ABSENCE OF MetS 
1 1 (33.3) 2 (66.7) 
2 1 (33.3) 2 (66.7) 
3 34 (65.4) 18 (34.6) 
4 54 (66.7) 27 (33.3) 
5 18 (85.1) 3 (14.3) 
df = 4, p = 0.165  
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